GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Cash Flow from Operations

Therapeutic Solutions International (Therapeutic Solutions International) Cash Flow from Operations : $-1.06 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, Therapeutic Solutions International's Net Income From Continuing Operations was $-0.48 Mil. Its Depreciation, Depletion and Amortization was $0.08 Mil. Its Change In Working Capital was $0.09 Mil. Its cash flow from deferred tax was $0.00 Mil. Its Cash from Discontinued Operating Activities was $0.00 Mil. Its Asset Impairment Charge was $0.00 Mil. Its Stock Based Compensation was $0.20 Mil. And its Cash Flow from Others was $-0.09 Mil. In all, Therapeutic Solutions International's Cash Flow from Operations for the three months ended in Dec. 2023 was $-0.21 Mil.


Therapeutic Solutions International Cash Flow from Operations Historical Data

The historical data trend for Therapeutic Solutions International's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Cash Flow from Operations Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.31 -0.66 -0.72 -1.04 -1.06

Therapeutic Solutions International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.39 -0.20 -0.34 -0.31 -0.21

Therapeutic Solutions International Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Therapeutic Solutions International's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Therapeutic Solutions International's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Therapeutic Solutions International  (OTCPK:TSOI) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Therapeutic Solutions International's net income from continuing operations for the three months ended in Dec. 2023 was $-0.48 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Therapeutic Solutions International's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $0.08 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Therapeutic Solutions International's change in working capital for the three months ended in Dec. 2023 was $0.09 Mil. It means Therapeutic Solutions International's working capital increased by $0.09 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Therapeutic Solutions International's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Therapeutic Solutions International's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Therapeutic Solutions International's asset impairment charge for the three months ended in Dec. 2023 was $0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Therapeutic Solutions International's stock based compensation for the three months ended in Dec. 2023 was $0.20 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Therapeutic Solutions International's cash flow from others for the three months ended in Dec. 2023 was $-0.09 Mil.


Therapeutic Solutions International Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Traded in Other Exchanges
N/A
Address
701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
Executives
Thomas Ichim director 211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg officer: CFO 1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon director, officer: Chairman, President, CEO 4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman officer: VP, Training & Education 2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd director, 10 percent owner PO BOX 2145, RANCHO SANTA FE CA 92067

Therapeutic Solutions International (Therapeutic Solutions International) Headlines

From GuruFocus